CANbridge Pharmaceutical Inc that is focused on rare disease therapies has raised $98 million in its Series D round led by global private equity firm General Atlantic and existing investor WuXi AppTec, a Hong Kong and Shanghai dual-listed innovative drug maker, according to a company statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
